aluates Reports

$ 0.0

Automative

Global Cancer Immunotherapy Drugs Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-36X17113

BUY CHAPTERS

Global Cancer Immunotherapy Drugs Market Research Report 2024

Code: QYRE-Auto-36X17113

Report

May 2024

Pages:94

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

Cancer Immunotherapy Drugs Market

Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)

The global Cancer Immunotherapy Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Cancer Immunotherapy Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Cancer Immunotherapy Drugs in Lung Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Cancer Immunotherapy Drugs include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drugs.

The Cancer Immunotherapy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Immunotherapy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Immunotherapy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Cancer Immunotherapy Drugs Market Report

Report Metric	Details
Report Name	Cancer Immunotherapy Drugs Market
Segment by Type	Immune Checkpoint Inhibitors Cytokine-Based Immunotherapy CAR-T Cell Therapy Other
Segment by Application	Lung Cancer Breast Cancer Prostate Cancer Blood-related Cancer Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer Immunotherapy Drugs Market report?

Ans: The main players in the Cancer Immunotherapy Drugs Market are AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Cancer Immunotherapy Drugs Market report?

Ans: The Applications covered in the Cancer Immunotherapy Drugs Market report are Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer, Other

What are the Type segmentation covered in the Cancer Immunotherapy Drugs Market report?

Ans: The Types covered in the Cancer Immunotherapy Drugs Market report are Immune Checkpoint Inhibitors, Cytokine-Based Immunotherapy, CAR-T Cell Therapy, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Immune Checkpoint Inhibitors

1.2.3 Cytokine-Based Immunotherapy

1.2.4 CAR-T Cell Therapy

1.2.5 Other

1.3 Market by Application

1.3.1 Global Cancer Immunotherapy Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Lung Cancer

1.3.3 Breast Cancer

1.3.4 Prostate Cancer

1.3.5 Blood-related Cancer

1.3.6 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cancer Immunotherapy Drugs Market Perspective (2019-2030)

2.2 Global Cancer Immunotherapy Drugs Growth Trends by Region

2.2.1 Global Cancer Immunotherapy Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cancer Immunotherapy Drugs Historic Market Size by Region (2019-2024)

2.2.3 Cancer Immunotherapy Drugs Forecasted Market Size by Region (2025-2030)

2.3 Cancer Immunotherapy Drugs Market Dynamics

2.3.1 Cancer Immunotherapy Drugs Industry Trends

2.3.2 Cancer Immunotherapy Drugs Market Drivers

2.3.3 Cancer Immunotherapy Drugs Market Challenges

2.3.4 Cancer Immunotherapy Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cancer Immunotherapy Drugs Players by Revenue

3.1.1 Global Top Cancer Immunotherapy Drugs Players by Revenue (2019-2024)

3.1.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Cancer Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Cancer Immunotherapy Drugs Revenue

3.4 Global Cancer Immunotherapy Drugs Market Concentration Ratio

3.4.1 Global Cancer Immunotherapy Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Immunotherapy Drugs Revenue in 2023

3.5 Global Key Players of Cancer Immunotherapy Drugs Head office and Area Served

3.6 Global Key Players of Cancer Immunotherapy Drugs, Product and Application

3.7 Global Key Players of Cancer Immunotherapy Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer Immunotherapy Drugs Breakdown Data by Type

4.1 Global Cancer Immunotherapy Drugs Historic Market Size by Type (2019-2024)

4.2 Global Cancer Immunotherapy Drugs Forecasted Market Size by Type (2025-2030)

5 Cancer Immunotherapy Drugs Breakdown Data by Application

5.1 Global Cancer Immunotherapy Drugs Historic Market Size by Application (2019-2024)

5.2 Global Cancer Immunotherapy Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cancer Immunotherapy Drugs Market Size (2019-2030)

6.2 North America Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Cancer Immunotherapy Drugs Market Size by Country (2019-2024)

6.4 North America Cancer Immunotherapy Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cancer Immunotherapy Drugs Market Size (2019-2030)

7.2 Europe Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Cancer Immunotherapy Drugs Market Size by Country (2019-2024)

7.4 Europe Cancer Immunotherapy Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Cancer Immunotherapy Drugs Market Size (2019-2030)

8.2 Asia-Pacific Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Cancer Immunotherapy Drugs Market Size (2019-2030)

9.2 Latin America Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Cancer Immunotherapy Drugs Market Size by Country (2019-2024)

9.4 Latin America Cancer Immunotherapy Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cancer Immunotherapy Drugs Market Size (2019-2030)

10.2 Middle East & Africa Cancer Immunotherapy Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Cancer Immunotherapy Drugs Introduction

11.1.4 AbbVie Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.1.5 AbbVie Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Introduction

11.2.4 Johnson & Johnson Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.2.5 Johnson & Johnson Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Cancer Immunotherapy Drugs Introduction

11.3.4 Novartis Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.3.5 Novartis Recent Development

11.4 Gilead Sciences

11.4.1 Gilead Sciences Company Details

11.4.2 Gilead Sciences Business Overview

11.4.3 Gilead Sciences Cancer Immunotherapy Drugs Introduction

11.4.4 Gilead Sciences Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.4.5 Gilead Sciences Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Cancer Immunotherapy Drugs Introduction

11.5.4 Roche Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.5.5 Roche Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Introduction

11.6.4 Bristol-Myers Squibb Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Cancer Immunotherapy Drugs Introduction

11.7.4 Amgen Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Cancer Immunotherapy Drugs Introduction

11.8.4 AstraZeneca Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.8.5 AstraZeneca Recent Development

11.9 Merck & Co

11.9.1 Merck & Co Company Details

11.9.2 Merck & Co Business Overview

11.9.3 Merck & Co Cancer Immunotherapy Drugs Introduction

11.9.4 Merck & Co Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.9.5 Merck & Co Recent Development

11.10 Takeda

11.10.1 Takeda Company Details

11.10.2 Takeda Business Overview

11.10.3 Takeda Cancer Immunotherapy Drugs Introduction

11.10.4 Takeda Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.10.5 Takeda Recent Development

11.11 Merck KGaA

11.11.1 Merck KGaA Company Details

11.11.2 Merck KGaA Business Overview

11.11.3 Merck KGaA Cancer Immunotherapy Drugs Introduction

11.11.4 Merck KGaA Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.11.5 Merck KGaA Recent Development

11.12 Seagen

11.12.1 Seagen Company Details

11.12.2 Seagen Business Overview

11.12.3 Seagen Cancer Immunotherapy Drugs Introduction

11.12.4 Seagen Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.12.5 Seagen Recent Development

11.13 Eli Lilly

11.13.1 Eli Lilly Company Details

11.13.2 Eli Lilly Business Overview

11.13.3 Eli Lilly Cancer Immunotherapy Drugs Introduction

11.13.4 Eli Lilly Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.13.5 Eli Lilly Recent Development

11.14 Ono Pharmaceutical

11.14.1 Ono Pharmaceutical Company Details

11.14.2 Ono Pharmaceutical Business Overview

11.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Introduction

11.14.4 Ono Pharmaceutical Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.14.5 Ono Pharmaceutical Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Details

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Cancer Immunotherapy Drugs Introduction

11.15.4 Pfizer Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.15.5 Pfizer Recent Development

11.16 GSK

11.16.1 GSK Company Details

11.16.2 GSK Business Overview

11.16.3 GSK Cancer Immunotherapy Drugs Introduction

11.16.4 GSK Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.16.5 GSK Recent Development

11.17 Exelixis

11.17.1 Exelixis Company Details

11.17.2 Exelixis Business Overview

11.17.3 Exelixis Cancer Immunotherapy Drugs Introduction

11.17.4 Exelixis Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.17.5 Exelixis Recent Development

11.18 Regeneron

11.18.1 Regeneron Company Details

11.18.2 Regeneron Business Overview

11.18.3 Regeneron Cancer Immunotherapy Drugs Introduction

11.18.4 Regeneron Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.18.5 Regeneron Recent Development

11.19 Innovent

11.19.1 Innovent Company Details

11.19.2 Innovent Business Overview

11.19.3 Innovent Cancer Immunotherapy Drugs Introduction

11.19.4 Innovent Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.19.5 Innovent Recent Development

11.20 Hengrui Medicine

11.20.1 Hengrui Medicine Company Details

11.20.2 Hengrui Medicine Business Overview

11.20.3 Hengrui Medicine Cancer Immunotherapy Drugs Introduction

11.20.4 Hengrui Medicine Revenue in Cancer Immunotherapy Drugs Business (2019-2024)

11.20.5 Hengrui Medicine Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

List of Tables

Table 1. Global Cancer Immunotherapy Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Immune Checkpoint Inhibitors

Table 3. Key Players of Cytokine-Based Immunotherapy

Table 4. Key Players of CAR-T Cell Therapy

Table 5. Key Players of Other

Table 6. Global Cancer Immunotherapy Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Cancer Immunotherapy Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Cancer Immunotherapy Drugs Market Share by Region (2019-2024)

Table 10. Global Cancer Immunotherapy Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Cancer Immunotherapy Drugs Market Share by Region (2025-2030)

Table 12. Cancer Immunotherapy Drugs Market Trends

Table 13. Cancer Immunotherapy Drugs Market Drivers

Table 14. Cancer Immunotherapy Drugs Market Challenges

Table 15. Cancer Immunotherapy Drugs Market Restraints

Table 16. Global Cancer Immunotherapy Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Cancer Immunotherapy Drugs Market Share by Players (2019-2024)

Table 18. Global Top Cancer Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drugs as of 2023)

Table 19. Ranking of Global Top Cancer Immunotherapy Drugs Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Cancer Immunotherapy Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Cancer Immunotherapy Drugs, Headquarters and Area Served

Table 22. Global Key Players of Cancer Immunotherapy Drugs, Product and Application

Table 23. Global Key Players of Cancer Immunotherapy Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Cancer Immunotherapy Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2019-2024)

Table 27. Global Cancer Immunotherapy Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2025-2030)

Table 29. Global Cancer Immunotherapy Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2019-2024)

Table 31. Global Cancer Immunotherapy Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2025-2030)

Table 33. North America Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Cancer Immunotherapy Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Cancer Immunotherapy Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 48. AbbVie Company Details

Table 49. AbbVie Business Overview

Table 50. AbbVie Cancer Immunotherapy Drugs Product

Table 51. AbbVie Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 52. AbbVie Recent Development

Table 53. Johnson & Johnson Company Details

Table 54. Johnson & Johnson Business Overview

Table 55. Johnson & Johnson Cancer Immunotherapy Drugs Product

Table 56. Johnson & Johnson Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 57. Johnson & Johnson Recent Development

Table 58. Novartis Company Details

Table 59. Novartis Business Overview

Table 60. Novartis Cancer Immunotherapy Drugs Product

Table 61. Novartis Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 62. Novartis Recent Development

Table 63. Gilead Sciences Company Details

Table 64. Gilead Sciences Business Overview

Table 65. Gilead Sciences Cancer Immunotherapy Drugs Product

Table 66. Gilead Sciences Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 67. Gilead Sciences Recent Development

Table 68. Roche Company Details

Table 69. Roche Business Overview

Table 70. Roche Cancer Immunotherapy Drugs Product

Table 71. Roche Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 72. Roche Recent Development

Table 73. Bristol-Myers Squibb Company Details

Table 74. Bristol-Myers Squibb Business Overview

Table 75. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product

Table 76. Bristol-Myers Squibb Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 77. Bristol-Myers Squibb Recent Development

Table 78. Amgen Company Details

Table 79. Amgen Business Overview

Table 80. Amgen Cancer Immunotherapy Drugs Product

Table 81. Amgen Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 82. Amgen Recent Development

Table 83. AstraZeneca Company Details

Table 84. AstraZeneca Business Overview

Table 85. AstraZeneca Cancer Immunotherapy Drugs Product

Table 86. AstraZeneca Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 87. AstraZeneca Recent Development

Table 88. Merck & Co Company Details

Table 89. Merck & Co Business Overview

Table 90. Merck & Co Cancer Immunotherapy Drugs Product

Table 91. Merck & Co Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 92. Merck & Co Recent Development

Table 93. Takeda Company Details

Table 94. Takeda Business Overview

Table 95. Takeda Cancer Immunotherapy Drugs Product

Table 96. Takeda Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 97. Takeda Recent Development

Table 98. Merck KGaA Company Details

Table 99. Merck KGaA Business Overview

Table 100. Merck KGaA Cancer Immunotherapy Drugs Product

Table 101. Merck KGaA Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 102. Merck KGaA Recent Development

Table 103. Seagen Company Details

Table 104. Seagen Business Overview

Table 105. Seagen Cancer Immunotherapy Drugs Product

Table 106. Seagen Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 107. Seagen Recent Development

Table 108. Eli Lilly Company Details

Table 109. Eli Lilly Business Overview

Table 110. Eli Lilly Cancer Immunotherapy Drugs Product

Table 111. Eli Lilly Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 112. Eli Lilly Recent Development

Table 113. Ono Pharmaceutical Company Details

Table 114. Ono Pharmaceutical Business Overview

Table 115. Ono Pharmaceutical Cancer Immunotherapy Drugs Product

Table 116. Ono Pharmaceutical Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 117. Ono Pharmaceutical Recent Development

Table 118. Pfizer Company Details

Table 119. Pfizer Business Overview

Table 120. Pfizer Cancer Immunotherapy Drugs Product

Table 121. Pfizer Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 122. Pfizer Recent Development

Table 123. GSK Company Details

Table 124. GSK Business Overview

Table 125. GSK Cancer Immunotherapy Drugs Product

Table 126. GSK Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 127. GSK Recent Development

Table 128. Exelixis Company Details

Table 129. Exelixis Business Overview

Table 130. Exelixis Cancer Immunotherapy Drugs Product

Table 131. Exelixis Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 132. Exelixis Recent Development

Table 133. Regeneron Company Details

Table 134. Regeneron Business Overview

Table 135. Regeneron Cancer Immunotherapy Drugs Product

Table 136. Regeneron Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 137. Regeneron Recent Development

Table 138. Innovent Company Details

Table 139. Innovent Business Overview

Table 140. Innovent Cancer Immunotherapy Drugs Product

Table 141. Innovent Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 142. Innovent Recent Development

Table 143. Hengrui Medicine Company Details

Table 144. Hengrui Medicine Business Overview

Table 145. Hengrui Medicine Cancer Immunotherapy Drugs Product

Table 146. Hengrui Medicine Revenue in Cancer Immunotherapy Drugs Business (2019-2024) & (US$ Million)

Table 147. Hengrui Medicine Recent Development

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Cancer Immunotherapy Drugs Picture

Figure 2. Global Cancer Immunotherapy Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Cancer Immunotherapy Drugs Market Share by Type: 2023 VS 2030

Figure 4. Immune Checkpoint Inhibitors Features

Figure 5. Cytokine-Based Immunotherapy Features

Figure 6. CAR-T Cell Therapy Features

Figure 7. Other Features

Figure 8. Global Cancer Immunotherapy Drugs Market Size by Application (2024-2030) & (US$ Million)

Figure 9. Global Cancer Immunotherapy Drugs Market Share by Application: 2023 VS 2030

Figure 10. Lung Cancer Case Studies

Figure 11. Breast Cancer Case Studies

Figure 12. Prostate Cancer Case Studies

Figure 13. Blood-related Cancer Case Studies

Figure 14. Other Case Studies

Figure 15. Cancer Immunotherapy Drugs Report Years Considered

Figure 16. Global Cancer Immunotherapy Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Cancer Immunotherapy Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Cancer Immunotherapy Drugs Market Share by Region: 2023 VS 2030

Figure 19. Global Cancer Immunotherapy Drugs Market Share by Players in 2023

Figure 20. Global Top Cancer Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drugs as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Cancer Immunotherapy Drugs Revenue in 2023

Figure 22. North America Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Cancer Immunotherapy Drugs Market Share by Country (2019-2030)

Figure 24. United States Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Cancer Immunotherapy Drugs Market Share by Country (2019-2030)

Figure 28. Germany Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Cancer Immunotherapy Drugs Market Share by Region (2019-2030)

Figure 36. China Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Cancer Immunotherapy Drugs Market Share by Country (2019-2030)

Figure 44. Mexico Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Cancer Immunotherapy Drugs Market Share by Country (2019-2030)

Figure 48. Turkey Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. UAE Cancer Immunotherapy Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. AbbVie Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 52. Johnson & Johnson Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 54. Gilead Sciences Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 55. Roche Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 57. Amgen Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 58. AstraZeneca Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 59. Merck & Co Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 60. Takeda Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 61. Merck KGaA Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 62. Seagen Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 63. Eli Lilly Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 64. Ono Pharmaceutical Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 65. Pfizer Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 66. GSK Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 67. Exelixis Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 68. Regeneron Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 69. Innovent Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 70. Hengrui Medicine Revenue Growth Rate in Cancer Immunotherapy Drugs Business (2019-2024)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Cancer Immunosuppressant Treatment Market Research Report 2024

Global Immunosuppressants in Cancer Therapy Market Research Report 2024

Global Immunotherapy Drugs Market Research Report 2024

Immuno oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Immunotherapeutic Drugs Market Insights Forecast to 2030

Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Immunotherapy Market Insights Forecast to 2030

Global Immuno oncology Therapy Market Insights Forecast to 2030

Global Cancer Immunotherapies Market Insights Forecast to 2030

Global Cell Immunotherapy Platform Market Research Report 2024

Global CAR T Cell Immunotherapy Market Insights Forecast to 2030

Global T Cell Immunotherapy Market Research Report 2025

Global Tumor Immune Cell Therapy Market Research Report 2024

Global Cancer Biotherapy Market Insights Forecast to 2030

Global TCR T Cellular Immunotherapy Market Research Report 2024

Global Immuno Cell Therapy Market Research Report 2024

Global Cancer Targeted Drug Market Research Report 2025

Global Immuno Oncology Service Market Research Report 2024

Oncology Immunotherapy Market

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions